OVID Stock Overview
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Ovid Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.11 |
| 52 Week High | US$4.14 |
| 52 Week Low | US$2.57 |
| Beta | 0.69 |
| 1 Month Change | 13.92% |
| 3 Month Change | -0.96% |
| 1 Year Change | 2.98% |
| 3 Year Change | -13.37% |
| 5 Year Change | 59.49% |
| Change since IPO | -74.61% |
Recent News & Updates
Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024
Apr 09We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth
Nov 10
Recent updates
Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024
Apr 09We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth
Nov 10Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth
Jun 27Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation
Mar 13Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?
Sep 09Ovid Therapeutics GAAP EPS of -$0.21 beats by $0.04
Aug 09We Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully
Jun 09Ovid Therapeutics: Good Entry Point For Investors
Jun 18Ovid Therapeutics appoints Jeff Rona as CFO
Jun 04Ovid Therapeutics Inc. (NASDAQ:OVID) Could Be Less Than A Year Away From Profitability
Apr 16Analysts Just Made A Captivating Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasts
Mar 20Ovid Therapeutics Inc. (NASDAQ:OVID) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates
Mar 18We're Keeping An Eye On Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate
Mar 01Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?
Jan 25Revisiting Ovid Therapeutics
Jan 14Would Shareholders Who Purchased Ovid Therapeutics' (NASDAQ:OVID) Stock Three Years Be Happy With The Share price Today?
Dec 21Ovid Therapeutics misses goal in Angelman syndrome treatment
Dec 01Shareholder Returns
| OVID | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.2% | -4.2% | -3.7% |
| 1Y | 3.0% | -2.0% | 20.5% |
Return vs Industry: OVID exceeded the US Biotechs industry which returned -1.7% over the past year.
Return vs Market: OVID underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| OVID volatility | |
|---|---|
| OVID Average Weekly Movement | 7.4% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: OVID's share price has been volatile over the past 3 months.
Volatility Over Time: OVID's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 40 | Jeremy Levin | www.ovidrx.com |
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome.
Ovid Therapeutics Inc. Fundamentals Summary
| OVID fundamental statistics | |
|---|---|
| Market cap | US$224.15m |
| Earnings (TTM) | -US$52.34m |
| Revenue (TTM) | US$391.70k |
561.4x
P/S Ratio-4.2x
P/E RatioIs OVID overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OVID income statement (TTM) | |
|---|---|
| Revenue | US$391.70k |
| Cost of Revenue | US$0 |
| Gross Profit | US$391.70k |
| Other Expenses | US$52.73m |
| Earnings | -US$52.34m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.74 |
| Gross Margin | 100.00% |
| Net Profit Margin | -13,362.17% |
| Debt/Equity Ratio | 0% |
How did OVID perform over the long term?
See historical performance and comparison